PL2609082T3 - Imidazo[4,5-C]chinoliny jako inhibitory DNA-PK - Google Patents
Imidazo[4,5-C]chinoliny jako inhibitory DNA-PKInfo
- Publication number
- PL2609082T3 PL2609082T3 PL11748260T PL11748260T PL2609082T3 PL 2609082 T3 PL2609082 T3 PL 2609082T3 PL 11748260 T PL11748260 T PL 11748260T PL 11748260 T PL11748260 T PL 11748260T PL 2609082 T3 PL2609082 T3 PL 2609082T3
- Authority
- PL
- Poland
- Prior art keywords
- quinolines
- imidazo
- inhibitors
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010035744A DE102010035744A1 (de) | 2010-08-28 | 2010-08-28 | Imidazolonylchinoline |
EP11748260.4A EP2609082B1 (de) | 2010-08-28 | 2011-07-26 | Imidazo[4,5-c]chinoline als dna-pk-inhibitoren |
PCT/EP2011/003744 WO2012028233A1 (de) | 2010-08-28 | 2011-07-26 | Imidazo [4,5-c]chinoline als dna-pk-inhibitoren |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2609082T3 true PL2609082T3 (pl) | 2015-07-31 |
Family
ID=44509164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11748260T PL2609082T3 (pl) | 2010-08-28 | 2011-07-26 | Imidazo[4,5-C]chinoliny jako inhibitory DNA-PK |
Country Status (25)
Country | Link |
---|---|
US (3) | US9000153B2 (pl) |
EP (1) | EP2609082B1 (pl) |
JP (1) | JP5882329B2 (pl) |
KR (1) | KR101912475B1 (pl) |
CN (1) | CN103068803B (pl) |
AR (1) | AR082728A1 (pl) |
AU (1) | AU2011298013B9 (pl) |
BR (1) | BR112013004613B1 (pl) |
CA (1) | CA2809553C (pl) |
CY (1) | CY1116281T1 (pl) |
DE (1) | DE102010035744A1 (pl) |
DK (1) | DK2609082T3 (pl) |
EA (1) | EA022095B1 (pl) |
ES (1) | ES2536313T3 (pl) |
HK (1) | HK1184154A1 (pl) |
HR (1) | HRP20150489T1 (pl) |
HU (1) | HUE025692T2 (pl) |
IL (1) | IL224903A (pl) |
MX (1) | MX338150B (pl) |
PL (1) | PL2609082T3 (pl) |
PT (1) | PT2609082E (pl) |
RS (1) | RS54038B1 (pl) |
SG (1) | SG187954A1 (pl) |
SI (1) | SI2609082T1 (pl) |
WO (1) | WO2012028233A1 (pl) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3459942T3 (pl) | 2012-04-24 | 2021-10-11 | Vertex Pharmaceuticals Incorporated | Inhibitory DNA-PK |
BR112015021888B1 (pt) * | 2013-03-12 | 2022-08-09 | Vertex Pharmaceuticals Incorporated | Inibidores de dna-pk, seus usos e composição farmacêutica |
SI3057953T1 (sl) | 2013-10-17 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk |
NO2714752T3 (pl) | 2014-05-08 | 2018-04-21 | ||
CN111689963A (zh) * | 2015-04-02 | 2020-09-22 | 默克专利股份公司 | 咪唑酮基喹啉和其作为atm激酶抑制剂的用途 |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
JP2019529475A (ja) | 2016-09-27 | 2019-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Dna損傷剤とdna−pk阻害剤との組合せ物を使用する、がんを処置するための方法 |
WO2018183868A1 (en) * | 2017-03-31 | 2018-10-04 | Bioventures, Llc | Inhibitors of dna pk and uses thereof |
KR20200040269A (ko) * | 2017-08-11 | 2020-04-17 | 메르크 파텐트 게엠베하 | 3-플루오로-4-[7-메톡시-3-메틸-8-(1-메틸-1H-피라졸-4-일)-2-옥소-2,3-디하이드로-이미다조[4,5-c]퀴놀린-1-일]-벤조니트릴을 포함하는 약학 제제 |
WO2019177971A1 (en) * | 2018-03-12 | 2019-09-19 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
US20210353614A1 (en) * | 2018-03-14 | 2021-11-18 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
TWI820146B (zh) | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
CN111909144A (zh) * | 2019-05-10 | 2020-11-10 | 山东轩竹医药科技有限公司 | 喹唑啉类dna-pk抑制剂 |
WO2021005077A1 (en) | 2019-07-10 | 2021-01-14 | Merck Patent Gmbh | Pharmaceutical preparation |
US20230014730A1 (en) | 2019-09-23 | 2023-01-19 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
IL292613A (en) | 2019-11-01 | 2022-07-01 | Ares Trading Sa | Combined inhibition of pd-1, tgf-beta and atm along with radiotherapy for cancer treatment |
EP4168010A1 (en) | 2020-06-18 | 2023-04-26 | Merck Patent GmbH | Compounds for the treatment of viral infections |
EP4171651A1 (en) | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atm inhibitor |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69111077T2 (de) | 1990-11-06 | 1995-11-02 | Pfizer | Chinazolinderivate um die antitumorwirkung zu verbessern. |
AU4972900A (en) | 1999-04-08 | 2000-11-14 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
CA2510375A1 (en) * | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
NZ545412A (en) * | 2003-08-27 | 2008-12-24 | Coley Pharm Group Inc | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
EP1673087B1 (en) * | 2003-10-03 | 2015-05-13 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
CN1830964B (zh) * | 2005-03-11 | 2011-06-15 | 中国科学院上海药物研究所 | 4-取代苯氨基-3-硝基喹啉类化合物及其制备方法和用途 |
AR054438A1 (es) | 2005-04-15 | 2007-06-27 | Kudos Pharm Ltd | Inhibidores de adn -pk |
GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CA2628131C (en) * | 2005-11-04 | 2012-03-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods |
NZ576357A (en) * | 2006-11-20 | 2011-01-28 | Novartis Ag | Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
WO2009130469A1 (en) * | 2008-04-25 | 2009-10-29 | Kudos Pharmaceuticals Limited | Dna-pk inhibitors |
EP2303890A4 (en) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
JP5347628B2 (ja) * | 2009-03-26 | 2013-11-20 | 富士通株式会社 | マイクロ構造体 |
US20100311714A1 (en) * | 2009-06-04 | 2010-12-09 | Pascal Furet | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS |
PE20120224A1 (es) * | 2009-06-04 | 2012-04-04 | Novartis Ag | Derivados de 1h-imidazo-[4,5-c]-quinolinona |
CA2766967A1 (en) * | 2009-06-30 | 2011-01-06 | Piramal Life Sciences Limited | Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation |
-
2010
- 2010-08-28 DE DE102010035744A patent/DE102010035744A1/de not_active Withdrawn
-
2011
- 2011-07-26 MX MX2013002259A patent/MX338150B/es active IP Right Grant
- 2011-07-26 PL PL11748260T patent/PL2609082T3/pl unknown
- 2011-07-26 WO PCT/EP2011/003744 patent/WO2012028233A1/de active Application Filing
- 2011-07-26 DK DK11748260.4T patent/DK2609082T3/en active
- 2011-07-26 ES ES11748260.4T patent/ES2536313T3/es active Active
- 2011-07-26 PT PT117482604T patent/PT2609082E/pt unknown
- 2011-07-26 SG SG2013013966A patent/SG187954A1/en unknown
- 2011-07-26 BR BR112013004613-9A patent/BR112013004613B1/pt active IP Right Grant
- 2011-07-26 SI SI201130493T patent/SI2609082T1/sl unknown
- 2011-07-26 EP EP11748260.4A patent/EP2609082B1/de active Active
- 2011-07-26 JP JP2013526334A patent/JP5882329B2/ja active Active
- 2011-07-26 RS RS20150330A patent/RS54038B1/en unknown
- 2011-07-26 CA CA2809553A patent/CA2809553C/en active Active
- 2011-07-26 US US13/819,488 patent/US9000153B2/en active Active
- 2011-07-26 AU AU2011298013A patent/AU2011298013B9/en active Active
- 2011-07-26 CN CN201180041966.4A patent/CN103068803B/zh active Active
- 2011-07-26 EA EA201300288A patent/EA022095B1/ru not_active IP Right Cessation
- 2011-07-26 HU HUE11748260A patent/HUE025692T2/en unknown
- 2011-07-26 KR KR1020137006794A patent/KR101912475B1/ko active IP Right Grant
- 2011-08-26 AR ARP110103113A patent/AR082728A1/es active IP Right Grant
-
2013
- 2013-02-25 IL IL224903A patent/IL224903A/en active IP Right Grant
- 2013-10-17 HK HK13111720.9A patent/HK1184154A1/zh unknown
-
2015
- 2015-04-01 US US14/676,125 patent/US9598408B2/en active Active
- 2015-05-07 HR HRP20150489TT patent/HRP20150489T1/hr unknown
- 2015-05-14 CY CY20151100429T patent/CY1116281T1/el unknown
-
2017
- 2017-02-27 US US15/443,349 patent/US20170166567A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL224903A (en) | Imidzo [c – 5,4] quinolines as DNA inhibitors | |
AP2806A (en) | 3H-imidazo[4,5-C] pyridine-6-carboxamides as anti-infammatory agents | |
IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
HK1180689A1 (en) | Imidazopyridines syk inhibitors syk | |
IL221823A (en) | Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors | |
EP2608669A4 (en) | NEW PYRAZOLO- [1,5-A-] PYRIMIDINE DERIVATIVES AS ANTI-MTOR HEMMER | |
HK1199018A1 (zh) | 作為 抑制劑的吡唑並喹啉衍生物 | |
ZA201203326B (en) | Imidazopyridine derivatives as jak inhibitors | |
ZA201304757B (en) | Imidazo [4,5-c] quinolin-2-one compound and its use as p13 kinase/mtor dual inhibitor | |
HK1189223A1 (zh) | 用作β分泌酶 抑制劑的 -二氫-吡咯並 吡嗪- -基胺衍生物 | |
IL216452A0 (en) | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | |
EP2634186A4 (en) | naphthyridine | |
EP2563125A4 (en) | AZAINDOLE AS JANUSKINASE HEMMER | |
GB201016880D0 (en) | Phosphodiesterase inhibitors | |
IL218032A0 (en) | Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors | |
ZA201206630B (en) | Hetaryl-[1,8]naphthyridine derivatives | |
EP2525659A4 (en) | PYRAZOLO [1,5-A] PYRIMIDINES COMPOUNDS AS MTOR INHIBITORS | |
IL214426A0 (en) | [1,2,4] triazollo [1,5-a] pyridines as kinase inhibitors | |
IL229993A (en) | 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2 | |
SI2588457T1 (sl) | Derivati pirazolokinolina kot inhibitorji dna pk | |
IL235829A0 (en) | Triazolo compounds as pde10 inhibitors | |
IL221479A0 (en) | Triazolo [4,5-b] pyridin derivatives | |
EP2523552A4 (en) | PYRAZOLO- [1,5-A] PYRIMIDINE AS MARK HEMMER | |
EP2565194A4 (en) | Imidazo [1,2-A] pyridine | |
EP2490693A4 (en) | Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS |